C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2026)

C4 Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $38000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $38000.0 in Q1 2026; TTM through Mar 2026 was $645000.0, a 258.33% increase from a year earlier, with the FY2025 full-year figure at $607000.0, up 237.22% from the prior year.
• Capital Expenditures eased to $38000.0 in Q1 2026 per CCCC's latest filing, from $582000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.3 million in Q3 2022 and bottomed at -$160000.0 in Q3 2025.
• The 5-year median for Capital Expenditures is $185000.0 (2025), against an average of $535266.7.
• Biggest YoY gain for Capital Expenditures was 14650.0% in 2025; the steepest drop was 193.57% in 2025.
• Year by year, Capital Expenditures stood at $1.5 million in 2022, then tumbled by 89.46% to $157000.0 in 2023, then plunged by 102.55% to -$4000.0 in 2024, then jumped by 14650.0% to $582000.0 in 2025, then plunged by 93.47% to $38000.0 in 2026.
• Per Business Quant, the three latest CCCC Capital Expenditures figures stand at $38000.0 (Q1 2026), $582000.0 (Q4 2025), and -$160000.0 (Q3 2025).